Monday 6th July 2020
|
11.30 |
Industry Symposium – Alexion Pharma UK |
|
|
Hypophosphatasia; recognition, diagnosis and management |
|
|
A presentation about HPP pathophysiology, signs & symptoms in all paediatric age groups, differential diagnosis, present a case study, give an overview of the HPP service structure, Managed Access Agreement treatment initiation criteria, (<18 year of age) and the value of referring appropriate patients to one of the 3 service centres. Dr Raja Padidela, Manchester
|
|
|
A presentation about signs & symptoms of HPP adult patients present with her experience in, diagnosing, differential diagnosis a case study,managing adult patients with hypophosphatasia and the value of collaborating with HPP service centres. Dr Katie Moss, London
Alexion products will be discussed in this meeting. This is an Alexion organised and funded meeting. Registration for this meeting is mandatory in order to attend. M/UK/STQ-H/0011 Prep: June 2020 |
|
14.30 |
Industry Symposium – Kyowa Kirin |
|
|
Top tips for caring for adults with X-linked Hypophosphataemia (XLH) – a case-based discussion
|
|
|
The symposium will be an engaging and interactive session, where the speakers will discuss XLH patient cases in order to:
Chair & speaker - Kassim Javaid, Oxford Speaker: Dr Jude Bubbear, Stanmore
|
|
|
M Kassim Javaid Associate Professor in Metabolic Bone Disease./Honorary consultant Rheumatologist, University of Oxford
Dr Javaid research interests include epidemiology of musculoskeletal diseases with a focus on rare diseases of the bone and secondary fracture prevention. He is co-chair for the International Osteoporosis Foundation Capture the Fracture programme and lead investigator for the RUDY study (www.rudystudy.org) which aims to understand the impact of rare bone diseases on patient reported outcomes.
Dr Bubbear Consultant Rheumatologist at the Royal National Orthopaedic Hospital, London
Dr Bubbear runs both Osteoporosis and Metabolic Bone Disease clinics. She is involved in clinical research, mostly in rare bone diseases, including Osteogenesis Imperfecta, X-linked Hypophophosphataemic rickets and Fibrodysplasia Ossificans Progressiva. When not working she is mostly to be found running or singing.
|
Tuesday 7th July 2020
|
16.00 |
Industry Symposium – UCB |
|
|
Osteoporosis: identification, risk stratification and management. UCB products will be discussed during this symposium. |
|
|
This promotional symposium is intended for healthcare professionals with a clinical and scientific interest in osteoporosis. |
|
|
Faculty: Dr Kassim Javaid, Associate Professor in Metabolic Bone Disease, NDORMS, University of Oxford NHS Trust, UK After completing medical training at Charing Cross and Westminster Medical School, Dr Javaid specialized in adult rheumatology. During that time, he completed an ARC Clinical Fellowship at the University of Southampton and then ARC travelling fellowship at UCSF. He is Associate Professor in Metabolic Bone Disease/ Honorary consultant Rheumatologist at Oxford. His research interests include epidemiology of musculoskeletal diseases with a focus on rare diseases of the bone and secondary fracture prevention. He is the clinical lead for the Royal College of Physicians RCP FLS-DB lead and co-chair for the International Osteoporosis Foundation Capture the Fracture programme.
Dr Beth Curtis, Clinical Lecturer in Rheumatology, MRC Lifecourse Epidemiology Unit, University of Southampton, UK Dr Beth Curtis recently completed a PhD at the MRC Lifecourse Epidemiology Unit, funded by the Wellcome Trust. Her research interests include early life influences on bone health and musculoskeletal epidemiology throughout the lifecourse. She is now combining research with clinical rheumatology as a Clinical Lecturer at the University of Southampton.
|
